GSK has launched a free supply program for the immuno-cancer drug Jemperli. According to related industries, GSK Korea is currently conducting Expanded Access Program (EAP) at 15 major medical institutions. Unlike the same type of immuno-cancer drug, Jemperli, a PD-1 inhibitor, plans to provide a first prescription opportunity to patients who need it as it was first approved for dMMR and MSI-H endometrial cancer, which is undergoing treatment or post-treatment with platinum-based systemic chemotherapy. Endometrial cancer is cancer that occurs in the endometrium which constitutes the inner wall of the uterine body and accounts for most uterine body cancer. Approximately one in four endometrial cancer patients is progr